Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study
May 19, 2021
Carlos Álvarez-Antonio, Graciela Meza-Sánchez, Carlos Calampa, Wilma Casanova, Cristiam Carey, Freddy Alava, Hugo Rodríguez-Ferrucci, Antonio M Quispe.
The Lancet Global Health
Alvarez-Antonio et al conducted a population-based cohort study in Iquitos, Peru, interviewing eligible individuals and collecting Rapid test results to examine the seroprevalence of IgG or IgM antibodies. The first test was completed July 13-18, 2020, as a baseline, and a second follow-up test was completed August 13-18, 2020. From the 716 participants included, results estimate a seroprevalence of 70% at baseline and an adjusted seroprevalence of 66% during the follow-up period. It was observed that there was a significantly higher seroprevalence of COVID-19 in children younger than 12 years, which was similar to that of adults older than 60. The seroprevalence findings at the two time points showed that most people were infected with COVID-19 by July 2020 and transmission was low, indicated by a small increase in seroprevalence in August 2020. Low transmission did not stop the second wave of infections experienced in Peru in January 2021, which may have been due to a COVID-19 variant.
Álvarez-Antonio C, Meza-Sánchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Glob Heal 2021; 0. DOI:10.1016/S2214-109X(21)00173-X.